Invest In MJ Charts:

Latest News Release from GW Pharmaceuticals plc

28  April  2015 

GW Pharmaceuticals plc announces pricing of U.S. Public Offering of ADSs Raising $179.2 Million on NASDAQ Global Market

London, UK, 28 April 2015: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company. GW will issue 1,600,000 American Depositary Shares (“ADSs”), representing 19,200,000 ordinary shares of GW, at a price to the public of $112.00 per ADS on the NASDAQ Global Market, raising gross proceeds of approximately $179.2 million (before deducting underwriting discount, commissions and offering expenses). GW has granted the underwriters a 30-day option to purchase up to an additional 240,000 ADSs at the public offering price less the underwriting discount. Closing of the offering is expected to occur on May 5, 2015.

Morgan Stanley, BofA Merrill Lynch and Cowen and Company are acting as joint book-running managers for the offering.Piper Jaffray & Co. is acting as lead manager.

The ADSs described above are being offered by GW pursuant to a shelf registration statement filed by GW with the Securities and Exchange Commission (“SEC”) that became automatically effective on May 7, 2014. The offering of the ADSs is being made only by means of a prospectus and prospectus supplement.  You may obtain these documents on the SEC’s website at http://www.sec.gov.  Alternatively, the prospectus and prospectus supplement may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; BofA Merrill Lynch, 222 Broadway, New York, NY 10038, attention: Prospectus Department, email: This email address is being protected from spambots. You need JavaScript enabled to view it.; Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Read Full Press Release

Mon Mar 14, 2016 10:24am
Cannabis drug succeeds in epilepsy, doubling value of GW Pharma